Matches in Nanopublications for { ?s ?p "[We therefore tested a rationally designed triple therapy consisting of an agonistic antibody against either TRAIL-R1 (mapatumumab/HGS-ETR1) or TRAIL-R2 (lexatumumab/HGS-ETR2) in combination with the established chemotherapeutic drug cisplatin in a panel of solid tumour cell lines derived from head and neck as well as colorectal carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 11 of
11
with 100 items per page.
- NP279779.RAdUslyzVVIy0oZS-VCdEVX9oam4KAxoTHLOOwbjE_Nb0130_assertion description "[We therefore tested a rationally designed triple therapy consisting of an agonistic antibody against either TRAIL-R1 (mapatumumab/HGS-ETR1) or TRAIL-R2 (lexatumumab/HGS-ETR2) in combination with the established chemotherapeutic drug cisplatin in a panel of solid tumour cell lines derived from head and neck as well as colorectal carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP279779.RAdUslyzVVIy0oZS-VCdEVX9oam4KAxoTHLOOwbjE_Nb0130_provenance.
- NP207391.RAWhGIJQ6yjVazjkftW6ci0K3GZhzRUHqpd2IlrwhKkgk130_assertion description "[We therefore tested a rationally designed triple therapy consisting of an agonistic antibody against either TRAIL-R1 (mapatumumab/HGS-ETR1) or TRAIL-R2 (lexatumumab/HGS-ETR2) in combination with the established chemotherapeutic drug cisplatin in a panel of solid tumour cell lines derived from head and neck as well as colorectal carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP207391.RAWhGIJQ6yjVazjkftW6ci0K3GZhzRUHqpd2IlrwhKkgk130_provenance.
- NP618229.RAVUyE7f9SSaoxrOjQb52Y_S2QqC_1OGhLKTgSixIQQrw130_assertion description "[We therefore tested a rationally designed triple therapy consisting of an agonistic antibody against either TRAIL-R1 (mapatumumab/HGS-ETR1) or TRAIL-R2 (lexatumumab/HGS-ETR2) in combination with the established chemotherapeutic drug cisplatin in a panel of solid tumour cell lines derived from head and neck as well as colorectal carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP618229.RAVUyE7f9SSaoxrOjQb52Y_S2QqC_1OGhLKTgSixIQQrw130_provenance.
- NP815931.RAbNH6kqBBP2W8siL7-FOlsh_U7a0HQYYcxI99XdOgnss130_assertion description "[We therefore tested a rationally designed triple therapy consisting of an agonistic antibody against either TRAIL-R1 (mapatumumab/HGS-ETR1) or TRAIL-R2 (lexatumumab/HGS-ETR2) in combination with the established chemotherapeutic drug cisplatin in a panel of solid tumour cell lines derived from head and neck as well as colorectal carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP815931.RAbNH6kqBBP2W8siL7-FOlsh_U7a0HQYYcxI99XdOgnss130_provenance.
- NP737410.RACZDfgTVTuSTwgiVYF-HhjNVdHQ10EoHE0Kle_TcB714130_assertion description "[We therefore tested a rationally designed triple therapy consisting of an agonistic antibody against either TRAIL-R1 (mapatumumab/HGS-ETR1) or TRAIL-R2 (lexatumumab/HGS-ETR2) in combination with the established chemotherapeutic drug cisplatin in a panel of solid tumour cell lines derived from head and neck as well as colorectal carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP737410.RACZDfgTVTuSTwgiVYF-HhjNVdHQ10EoHE0Kle_TcB714130_provenance.
- NP805786.RAsRIaNz27oavPLZWtvWyb2Hxvd8QfYriLg9CuhcqVr6w130_assertion description "[We therefore tested a rationally designed triple therapy consisting of an agonistic antibody against either TRAIL-R1 (mapatumumab/HGS-ETR1) or TRAIL-R2 (lexatumumab/HGS-ETR2) in combination with the established chemotherapeutic drug cisplatin in a panel of solid tumour cell lines derived from head and neck as well as colorectal carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP805786.RAsRIaNz27oavPLZWtvWyb2Hxvd8QfYriLg9CuhcqVr6w130_provenance.
- NP737408.RArBi76-yUdmw4fQeTlspqnjAKlImHH6DEvnNaZPK4RBc130_assertion description "[We therefore tested a rationally designed triple therapy consisting of an agonistic antibody against either TRAIL-R1 (mapatumumab/HGS-ETR1) or TRAIL-R2 (lexatumumab/HGS-ETR2) in combination with the established chemotherapeutic drug cisplatin in a panel of solid tumour cell lines derived from head and neck as well as colorectal carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP737408.RArBi76-yUdmw4fQeTlspqnjAKlImHH6DEvnNaZPK4RBc130_provenance.
- NP805938.RAINKX5t4oh0fi6qspCMYgLPoWgcmQYUVFPnlvNEbeVt0130_assertion description "[We therefore tested a rationally designed triple therapy consisting of an agonistic antibody against either TRAIL-R1 (mapatumumab/HGS-ETR1) or TRAIL-R2 (lexatumumab/HGS-ETR2) in combination with the established chemotherapeutic drug cisplatin in a panel of solid tumour cell lines derived from head and neck as well as colorectal carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP805938.RAINKX5t4oh0fi6qspCMYgLPoWgcmQYUVFPnlvNEbeVt0130_provenance.
- NP805716.RA-_PAKzohUOoI4vnZ1PgcmK--IHi0WsO1nrQVdQ6zuTM130_assertion description "[We therefore tested a rationally designed triple therapy consisting of an agonistic antibody against either TRAIL-R1 (mapatumumab/HGS-ETR1) or TRAIL-R2 (lexatumumab/HGS-ETR2) in combination with the established chemotherapeutic drug cisplatin in a panel of solid tumour cell lines derived from head and neck as well as colorectal carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP805716.RA-_PAKzohUOoI4vnZ1PgcmK--IHi0WsO1nrQVdQ6zuTM130_provenance.
- NP737409.RA_oEiZFMaMY2Qpl6Ri7LVQfw2wcdj9c07_7L2BuIYB6g130_assertion description "[We therefore tested a rationally designed triple therapy consisting of an agonistic antibody against either TRAIL-R1 (mapatumumab/HGS-ETR1) or TRAIL-R2 (lexatumumab/HGS-ETR2) in combination with the established chemotherapeutic drug cisplatin in a panel of solid tumour cell lines derived from head and neck as well as colorectal carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP737409.RA_oEiZFMaMY2Qpl6Ri7LVQfw2wcdj9c07_7L2BuIYB6g130_provenance.
- NP737411.RA4tp-ogAZJnL8V5Yjzg-PAtTGI3s9yj0E-wUc5aBxSnU130_assertion description "[We therefore tested a rationally designed triple therapy consisting of an agonistic antibody against either TRAIL-R1 (mapatumumab/HGS-ETR1) or TRAIL-R2 (lexatumumab/HGS-ETR2) in combination with the established chemotherapeutic drug cisplatin in a panel of solid tumour cell lines derived from head and neck as well as colorectal carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP737411.RA4tp-ogAZJnL8V5Yjzg-PAtTGI3s9yj0E-wUc5aBxSnU130_provenance.